Published in Physician Business Week, September 25th, 2007
The study published in the Sept. 12 issue of the Journal of the American Medical Association reports that use of pioglitazone (Actos(TM)) is associated with a significantly lower risk of death, myocardial infarction, or stroke among a diverse population of diabetic patients.
In a meta-analysis of 19 trials comprising 16,390 patients, researchers found that 4.4% (375) of the 8,554 patients prescribed pioglitazone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.